2014 Collaborative Awards

2-D Diffusion POC Assay for Self-monitoring of BNP

Ashutosh Chilkoti, PhD and Kristin Newby, MD

Project Aim: Develop a home test that monitors a biomarker in the blood and allows patients with chronic heart failure to upload results to their health record via smart phone so physicians can adjust medication levels.

 

Novel CaMKK2 Inhibitors for Neovascular Age-Related Macular Degeneration

Scott W. Cousins, MD, Donald P. McDonnell, PhD, Priyatham S. Mettu, MD, David Gooden, PhD, and Luigi Racioppi, PhD

Project Aim: Studying possible molecules that may reduce unwanted growth of blood vessels in the eye, with potential applications not only in age-related macular degeneration patients receiving currently approved therapies, but also patients with other back of the eye diseases.

 

Personalized Clinical Trials for Rare Orphan Disorders: Example of Pompe Disease

Dwight Koeberl, MD, PhD and Nenad Bursac, PhD

Project Aim: Improve the lives of those living with Pompe disease by increasing the effectiveness and decreasing cost of current enzyme replacement therapy. The project will culture muscle cells from patients and evaluate treatments in the laboratory, to ultimately improve efficacy and reduce the cost of the life-long enzyme replacement therapy required by patients with Pompe disease, a muscle-wasting disease.

 

Topical Inhibition of TRP Ion Channels for Treatment of Skin Inflammation and Pruritus

Wolfgang Liedtke, MD, PhD, Russell Hall, MD, and Jennifer Zhang, PhD

Project Aim: Improving the lives of people who have painful and itchy skin by creating a new topical medicine that can dial down the inflammation, pain and itch signals sent by skin cells.

 

Cues from the Native Immune Response: Targeting Cancer with Complement Factor H Antibodies

Edward F. Patz, Jr., MD, Michael J. Campa, PhD, Rex Bentley, MD, Elizabeth B. Gottlin, PhD, Tony Moody, MD, Larry Liao, MD, PhD, Bart Haynes, MD, and  James E. Herndon, PhD

Project Aim: Perform animal studies to determine which antibodies are most effective at inhibiting tumor growth, while also studying human cells to define factors that predispose patients to benefit from the antibody treatments.  The end goal is to optimize the best option for the first human-derived antibodies used to fight lung tumors.